Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Amgen (AMGN - Analyst Report) recently presented data on its cardiovascular candidate, omecamtiv mecarbil, at the European Society of Cardiology. Amgen said that omecamtiv mecarbil failed to meet its primary endpoint in the randomized, double-blind, placebo-controlled phase II ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) study.

The study (n=613), conducted in patients hospitalized with acute heart failure (AHF), evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of an intravenous formulation of omecamtiv mecarbil. Patients were treated in three, sequential, dose escalation cohorts of omecamtiv mecarbil or placebo for 48 hours.

Omecamtiv mecarbil missed the primary endpoint of dyspnea (shortness of breath) response (measured by the 7-point Likert scale) through 48 hours. However, favorable dose and concentration-related trends on dyspnea response were observed. Moreover, the incidence of worsening heart failure within seven days of the commencement of treatment was 17% in the pooled placebo group and 13%, 8% and 9% on omecamtiv mecarbil in the first, second and third cohorts, respectively.

Heart rate or blood pressure was not adversely affected in patients on omecamtiv mecarbil. Omecamtiv mecarbil was also not associated with an increased incidence of tachyarrhythmias.

Amgen intends to wait for data from the COSMIC-HF study before deciding whether omecamtiv mecarbil should be moved into phase III development. Although omecamtiv mecarbil missed the primary endpoint, other data points from the study were encouraging especially the data related to the incidence of worsening heart failure.

We note that omecamtiv mecarbil is being developed in collaboration with Cytokinetics (CYTK - Snapshot Report). Cytokinetics’ shares were down more than 26% on the data.

Both Amgen and Cytokinetics are Zacks Rank #3 (Hold) stocks. At present, companies like Biogen Idec (BIIB - Analyst Report) and Gilead Sciences Inc. (GILD - Analyst Report) look attractive with both being Zacks Rank #1 (Strong Buy) stocks.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%